Filtered By:
Condition: Heart Attack
Countries: Spain Health
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 127 results found since Jan 2013.
COVID-19 pandemic on coronary artery and cerebrovascular diseases in Southern Spain: interrupted time series analysis
CONCLUSIONS: A decline in AMI and CVD daily hospital admissions during the first and second wave of COVID-19 pandemic was noted. Gender differences were observed, but no clear impact was observed in percutaneous interventions.PMID:37070925 | DOI:10.26355/eurrev_202304_31955
Source: European Review for Medical and Pharmacological Sciences - April 18, 2023 Category: Drugs & Pharmacology Authors: F J Rodr íguez-Cortés J E Jim énez-Hornero J F Alcal á-Diaz R M Mi ñarro-Del Moral J L Romero-Cabrera R Manfredini M A Rodr íguez-Borrego P J L ópez-Soto Source Type: research
Effect of Anticoagulation Duration on Stroke Incidence in Asian Patients With Left Ventricular Thrombus
Left ventricular thrombus (LVT) occurs in acute myocardial infarction (AMI) and in ischemic and nonischemic cardiomyopathies.1,2 LVT may result in embolic stroke.3 We read with interest the study by Lorente-Ros et al4 published in the American Journal of Cardiology. That study, conducted in a Spanish cohort, found that prolonged anticoagulation>12 months for LVT was associated with lower stroke risk. We aimed to study the generalizability of these results in an Asian population because the original article was a single-center study with limited representation.
Source: The American Journal of Cardiology - January 24, 2023 Category: Cardiology Authors: Fang Qin Goh, Aloysius S.T. Leow, Jamie S.Y. Ho, Benjamin Y.Q. Tan, Leonard L.L. Yeo, Ching-Hui Sia Source Type: research
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Diabetes Metab. 2023 Jan 3:101418. doi: 10.1016/j.diabet.2022.101418. Online ahead of print.ABSTRACTBACKGROUND: Continued expansion of indications for sodium-glucose cotransporter-2 inhibitors increases importance of evaluating cardiovascular and kidney efficacy and safety of empagliflozin in patients with type 2 diabetes compared to similar therapies.METHODS: The EMPRISE Europe and Asia study is a non-interventional cohort study using data from 2014-2019 in seven European (Denmark, Finland, Germany, Norway, Spain, Sweden, United Kingdom) and four Asian (Israel, Japan, South Korea, Taiwan) countries. Patients with type 2 d...
Source: Diabetes and Metabolism - January 7, 2023 Category: Endocrinology Authors: Avraham Karasik Stefanie Lanzinger Elise Chia-Hui Tan Daisuke Yabe Dae Jung Kim Wayne H-H Sheu Cheli Melzer-Cohen Reinhard W Holl Kyoung Hwa Ha Kamlesh Khunti Francesco Zaccardi Anuradhaa Subramanian Krishnarajah Nirantharakumar Thomas Nystr öm Leo Niska Source Type: research
Identification of Secondary Prevention Patients Eligible for PCSK9 Inhibitors Therapy According to the Routine Clinical Practice in Spain
ConclusionUp to 82% of patients with atherosclerotic CV disease do not achieve LDL-C levels recommended by the 2019 ESC/EAS guidelines despite being on optimized oral LLT therapy. In 17.9% of these patients LDL-C levels exceed 100 mg/dL, being eligible for PCSK9i in Spain.
Source: Advances in Therapy - December 16, 2022 Category: Drugs & Pharmacology Source Type: research
Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
Lancet Respir Med. 2022 Oct 10:S2213-2600(22)00298-3. doi: 10.1016/S2213-2600(22)00298-3. Online ahead of print.ABSTRACTBACKGROUND: COVID-19 disease is accompanied by a dysregulated immune response and hypercoagulability. The Anti-Coronavirus Therapies (ACT) inpatient trial aimed to evaluate anti-inflammatory therapy with colchicine and antithrombotic therapy with the combination of rivaroxaban and aspirin for prevention of disease progression in patients hospitalised with COVID-19.METHODS: The ACT inpatient, open-label, 2 × 2 factorial, randomised, controlled trial was done at 62 clinical centres in 11 countries. Patient...
Source: Respiratory Care - October 13, 2022 Category: Respiratory Medicine Authors: John W Eikelboom Sanjit S Jolly Emilie P Belley-Cote Richard P Whitlock Sumathy Rangarajan Lizhen Xu Laura Heenan Shrikant I Bangdiwala Maria Luz Diaz Rafael Diaz Afzalhussein Yusufali Sanjib Kumar Sharma Wadea M Tarhuni Mohamed Hassany Alvaro Avezum Will Source Type: research
